# Filing Detail

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0000950170-25-057350
Filing Date
2025-04-23
Accepted
2025-04-23 16:10:03
Documents
3

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEFA14A | rlay_defa14a_2025_notice.htm | DEFA14A | 18369
2 | GRAPHIC | img53889900_0.jpg | GRAPHIC | 1210485
3 | GRAPHIC | img53889900_1.jpg | GRAPHIC | 361846
| Complete submission text file | 0000950170-25-057350.txt |  | 2184722

Mailing Address 399 BINNEY STREET 2ND FLOOR CAMBRIDGE MA 02139
Business Address 399 BINNEY STREET 2ND FLOOR CAMBRIDGE MA 02139 617-370-8837
Relay Therapeutics, Inc. (Filer) CIK: 0001812364 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-39385 | Film No.: 25861537
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)